Antibodies News and Research

RSS

Three Ontario projects set to further knowledge and discovery in biomonitoring, drug development

As part of the Genome Canada Large-Scale Applied Research Project Competition, which as a whole awarded over $58 million to 16 projects across the country, the researchers in Ontario will be focusing on biomonitoring, understanding gene function with the aim of identifying genes or proteins for drug targets, and the creation of synthetic antibodies to target cancers and other diseases.

9 May 2011

Latest research on HIV immunity can help develop vaccine

Latest insights into immunity to HIV could help to develop a vaccine to build antibodies' defences against the disease, a University of Melbourne, Australia study has found.

7 May 2011

Enzon first quarter adjusted loss from continuing operations decreases to $4.2 million

Enzon Pharmaceuticals, Inc. today announced its financial results for the first quarter of 2011.

7 May 2011

VIMS develops new biosensor that can detect and track oil spills

A new biosensor which uses antibody-based technology has been shown to detect marine pollutants such as oil cheaper and faster than current technology. Tests of the new biosensor, published in Environmental Toxicology and Chemistry, reveal how it could be used for the early detection and tracking of oil spills.

6 May 2011

Neutralizing antibodies generated by immunization associated with protection against SIV infection

Using a monkey model of AIDS, scientists have identified a vaccine-generated immune-system response that correlates with protection against infection by the monkey version of HIV, called simian immunodeficiency virus (SIV). The researchers found that neutralizing antibodies generated by immunization were associated with protection against SIV infection.

6 May 2011

Rockland produces new Anti-NF-κB monoclonal antibody

Rockland Immunochemicals has produced a new Anti-NF-κB monoclonal antibody validated by several assays relevant for discovery including immunofluorescence microscopy, immunohistochemistry, western blotting and ELISA.

5 May 2011

Affitech, Cancer Research Technology sign deal to advance therapeutic antibodies

Cancer Research Technology, the commercial arm of Cancer Research UK, has signed a license agreement to grant antibody medicines company, Affitech A/S, exclusive rights to a CRT patent application and relevant know how to develop and use therapeutic antibodies that recognise and block the function of CCR4, a protein found on certain tumours - including early and late stage cervical cancer and oesophageal cancer.

4 May 2011

New nano-vault delivery system can fight cancer

UCLA scientists have discovered a way to wake up the immune system to fight cancer by delivering an immune system-stimulating protein in a nanoscale container called a vault directly into lung cancer tumors, harnessing the body's natural defenses to fight disease growth.

4 May 2011

TPO antibodies linked to abnormal thyroid levels in women after giving birth

Almost 1 in 20 women who gives birth will go on to develop thyroid problems within two years, according to a new study presented at the European Congress of Endocrinology in Rotterdam. This could have significant implications for the future health of the mother and child, as well as potentially presenting problems for future pregnancies.

4 May 2011

Immunetics receives NIH grant for new confirmatory test trial in Chagas' disease

Immunetics, Inc. today announced it has been awarded a $2.4 million, 3-year Phase II SBIR grant by the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, to support clinical trials of the company's new confirmatory test for Chagas' disease, a serious and potentially fatal parasitic infection.

4 May 2011

Techne acquires Tocris Holdings

Techne Corporation announced today that it has acquired 100% ownership of Tocris Holdings Limited and subsidiaries, a leading supplier of reagents for non-clinical life science research.

3 May 2011

Animal studies reveal new route to treating heart disease

Scientists at Johns Hopkins have shown in laboratory experiments in mice that blocking the action of a signaling protein deep inside the heart’s muscle cells blunts the most serious ill effects of high blood pressure on the heart. These include heart muscle enlargement, scar tissue formation and loss of blood vessel growth.

2 May 2011

International Society of Nephrology honors BIDMC Co-director for immune tolerance research

Terry Strom, MD, Co-director of the Transplant Institute at Beth Israel Deaconess Medical Center and a leader in the field of immune tolerance research, was awarded the 2011 Alfred Newton Richards Award from the International Society of Nephrology during a program held earlier this month as part of the World Congress of Nephrology 2011 in Vancouver, Canada.

30 Apr 2011

Portuguese researcher to earn Bill & Melinda Gates Foundation award for new HIV therapy

João Gonçalves, from Faculdade de Farmácia e Instituto de Medicina Molecular, Lisbon, Portugal, to win a Grand Challenges Exploration Award

29 Apr 2011

MorphoSys reaches second clinical milestone with OncoMed Pharmaceuticals

MorphoSys AG announced today that it has received a milestone payment from OncoMed Pharmaceuticals in connection with the FDA acceptance of an IND for a HuCAL-derived, fully human antibody. The antibody OMP-18R5, which targets the Wnt signaling pathway, will be evaluated in a Phase 1 trial in the US in patients with advanced solid tumors.

29 Apr 2011

Simple blood test can diagnose early Parkinson's disease

In Parkinson's disease, the human body generates antibodies to combat the amyloid-producing protein alpha synuclein early in the course of the disease. A simple blood test that measures these antibodies can facilitate early diagnosis of the disorder, writes Ludmilla Morozova-Roche and her associates at Umeå University in Sweden in the latest issue of the journal PLoS One.

28 Apr 2011

AVEO reports total revenue of $133.6 million for first quarter 2011

AVEO Pharmaceuticals, Inc. today reviewed key first quarter accomplishments and reported consolidated financial results for the first quarter of 2011.

28 Apr 2011

IQ Therapeutics completes dosing in IQNLF Phase I trial for anthrax

IQ Therapeutics has completed the dosing of antibody IQNLF in a Phase I clinical trial. A total of 36 healthy volunteers participated in the randomized, placebo controlled, double blind, single dose-escalating study, intended to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of IQNLF.

27 Apr 2011

Lilly and Medtronic’s joint venture in Parkinson’s disease therapy

Lilly has already developed a protein called GDNF (glial cell line derived neurotrophic factor) known to preserve the function of neurons and Medtronic will provide a system that carries the medicine to a key area of the brain.

From Medtronic 26 Apr 2011

Caliber opens world's largest plant-made pharmaceutical facility in Bryan

Caliber Biotherapeutics, a fully-integrated biopharmaceutical company, announced the opening of the world's largest plant-made pharmaceutical manufacturing facility in Bryan, Texas, with the capability of producing 10-100 million doses of infectious vaccines per month, and hundreds of thousands of doses of protein biotherapeutics such as monoclonal antibodies.

26 Apr 2011